Abstract
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aged
-
Calcitonin / therapeutic use
-
Diphosphonates / therapeutic use
-
Estrogen Replacement Therapy
-
Female
-
Humans
-
Middle Aged
-
Osteoporosis / drug therapy*
-
Osteoporosis / prevention & control*
-
Postmenopause
-
Raloxifene Hydrochloride / adverse effects
-
Raloxifene Hydrochloride / therapeutic use*
-
Risk Factors
-
Selective Estrogen Receptor Modulators / adverse effects
-
Selective Estrogen Receptor Modulators / therapeutic use*
Substances
-
Diphosphonates
-
Selective Estrogen Receptor Modulators
-
Raloxifene Hydrochloride
-
Calcitonin